03 October 2020 : Clinical Research
Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension
Zirao Hao1BCDE, Yue Sun1BF, Yingzhen Wen1BF, Lijuan Cui1BF, Guiping Li1DF*, Yan Liu2AGDOI: 10.12659/MSM.925987
Med Sci Monit 2020; 26:e925987
Table 3 Medications use at admission and 3-month follow-up.
| Variables | With dapagliflozin (n=182) | Without dapagliflozin (n=304) | P |
|---|---|---|---|
| Aspirin, n (%) | 65 (35.7) | 115 (37.8) | 0.11 |
| Statins, n (%) | 73 (40.1) | 123 (40.5) | 0.821 |
| ACEI/ARB, n (%) | 80 (44.0) | 162 (53.3) | 0.007 |
| Beta-blocker, n (%) | 34 (18.7) | 52 (17.1) | 0.261 |
| Calcium channel blocker, n (%) | 59 (32.4) | 66 (21.7) | 0.02 |
| No. antihypertensive drugs | 1.6 (0.8–2.4) | 1.5 (0.7–2.3) | 0.31 |
| Metformin, n (%) | 158 (85.9) | 262 (86.2) | 0.19 |
| Sulfonylureas, n (%) | 80 (43.5) | 131 (43.1) | 0.99 |
| Alpha-glucoside inhibitor, n (%) | 38 (20.9) | 63 (20.7) | 0.91 |
| GLP-1 agonist, n (%) | 16 (8.8) | 29 (9.6) | 0.76 |
| DDP-4 inhibitor, n (%) | 13 (7.1) | 24 (7.9) | 0.45 |
| Thiazolidinedione, n (%) | 0 | 2 (0.7) | – |
| Insulin, n (%) | 15 (8.2) | 27 (8.9) | 0.22 |
| No. antidiabetic drugs | 1.7 (0.8–2.6) | 1.8 (0.9–2.8) | 0.17 |
| Fasting plasma glucose (mmol/L) | 6.3±0.5 | 6.2±0.4 | 0.60 |
| HbA1c (%) | 7.1±1.0 | 7.0±0.9 | 0.33 |
| Aspirin, n (%) | 65 (35.7) | 115 (37.8) | 0.10 |
| Statins, n (%) | 73 (40.1) | 123 (40.5) | 0.82 |
| ACEI/ARB, n (%) | 80 (44.0) | 168 (55.3) | 0.002 |
| Beta-blocker, n (%) | 31 (17.0) | 52 (17.1) | 0.19 |
| Calcium channel blocker, n (%) | 50 (27.2) | 77 (25.3) | 0.37 |
| No. antihypertensive drugs | 1.5 (0.7–2.3) | 1.6 (0.8–2.5) | 0.25 |
| Metformin, n (%) | 128 (69.6) | 282 (92.8) | <0.001 |
| Sulfonylureas, n (%) | 35 (19.0) | 140 (46.1) | 0.01 |
| Alpha-glucoside inhibitor, n (%) | 16 (8.7) | 69 (22.7) | 0.04 |
| GLP-1 agonist, n (%) | 10 (5.4) | 36 (11.8) | 0.09 |
| DDP-4 inhibitor, n (%) | 6 (3.3) | 32 (10.5) | 0.12 |
| Thiazolidinedione, n (%) | 0 | 4 (1.3) | – |
| Insulin, n (%) | 8 (4.3) | 32 (10.5) | 0.20 |
| Dapagliflozin, n (%) | 182 (100) | 0 | – |
| No. antidiabetic drugs | 2.1 (1.0–2.8) | 2.0 (0.9–2.7) | 0.15 |
| Fasting plasma glucose (mmol/L) | 6.0±0.4 | 6.1±0.3 | 0.32 |
| HbA1c (%) | 6.9±0.8 | 6.9±0.7 | 0.93 |
| ACEI/ARB – angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; GLP-1 agonist – glucagon-like peptide-1 agonist; DDP-4 inhibitor – dipeptidyl peptidase-4 inhibitor; HbA1c – glycated hemoglobin A1c; * | |||